Skip to main content

Bladder-builder welcomes windpipe

It's a big day in the consumer media, abuzz with the news that doctors linkurl:engineered a windpipe;https://www.the-scientist.com/article/daily/53878/ for a 30-year-old woman using her own stem cells, but at the offices of linkurl:Tengion,;https://www.the-scientist.com/article/daily/53878/ a Pennsylvania biotech currently building bladders using patient cells, it's just business as usual. This news "confirms what we know," said Gary Sender, chief financial officer at Tengion. "We know we are in

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
It's a big day in the consumer media, abuzz with the news that doctors linkurl:engineered a windpipe;https://www.the-scientist.com/article/daily/53878/ for a 30-year-old woman using her own stem cells, but at the offices of linkurl:Tengion,;https://www.the-scientist.com/article/daily/53878/ a Pennsylvania biotech currently building bladders using patient cells, it's just business as usual. This news "confirms what we know," said Gary Sender, chief financial officer at Tengion. "We know we are in an emerging field." Still, Sender added that any good news from the field of regenerative medicine is "very positive for Tengion." And for patients. "You and I as just citizens should be thrilled that there are advances in this technology," he said. "We think the more progress that's made in this field, the better." Just today (Nov 19), Tengion linkurl:announced;https://www.tengion.com/news/press/20081119.cfm that it completed a second closing of its Series C financing, receiving $21 million in additional equity. The company also recently wrapped up its phase 2 trial, consisting of 10 children with spina bifida, and plans to start a phase 3 sometime next year. (The company is not yet disclosing any data from the phase 2 trial.) The company is also moving forward with its plan to build bladders for patients with bladder cancer, a somewhat trickier procedure because of the risk that the patient's cancer cells could end up in the new organ. Sender said the company hopes to fill out an investigational new drug (IND) application early next year, and begin a clinical trial soon thereafter. When linkurl:I visited;https://www.the-scientist.com/article/daily/53878/ the company's main 2800 square-meter manufacturing facility last year, the labs were largely empty, but slowly filling with the state-of-the-art equipment needed to ramp up to a phase 3 trial. The facility is now set to go, Sender said. "We're ready to roll with the phase 3" trial.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi
Mapping Clonal Mosaicism in Aging Tissues

Mapping Clonal Mosaicism in Aging Tissues

Mission bio

Products

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo
Conceptual image of ice and frost.

The VAULT100 PRO: Inside the most advanced Stirling Ultracold ULT freezer ever built.

Stirling Ultracold logo